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E ffec t o f  isoflurane and sevoflurane on the magnitude and tim e  
c o u r se  o f  neurom uscular block produced by vecuronium, 
p a n cu ro n iu m  and atracurium f
L .  E .  H . V a n l in t h o u Tj L . H . D . J . B o o ij3 J . van  E g m o n d  and  E . N . R o bertso n
S u m m a r y
We have compared the ability of equipotent concen­
trations of isoflurane and sevoflurane to enhance 
the effect of non-depolarizing neuromuscular 
b locking drugs. Ninety ASA I and II patients of both 
sexes, aged 18-50yr, were stratified into three 
blocker groups (Vec, Pan and Atr), to undergo
30),
30),
neuromuscular block with vecuronium (n — 
pancuronium (n = 30) or atracurium (n -  
respectively. Within each group, patients were 
allocated randomly to one of three anaesthetic 
subgroups to undergo maintenance of anaesthesia 
w ith :  (1) alfentanil-nitrous oxide-oxygen (n 
1 0 ); (2) alfentanil-nitrous oxide-oxygen-isoflu- 
rane (/7 = 10); or (3) alfentanil-nitrous oxide- 
oxygen-sevoflurane (/7 = 10) anaesthesia. During 
maintenance of anaesthesia, end-tidal concen­
trations of isoflurane, sevoflurane and nitrous oxide 
were 0.95, 1.70 and 70%, respectively. Both the 
evoked integrated electromyogram and mechano- 
myogram of the adductor pollicis brevis muscle 
were measured simultaneously. In the Vec and Pan 
groups, a total dose of 40 ng kg~1 of vecuronium or 
pancuronium, respectively, was given, and in the 
A tr group a total dose of atracurium 100ngkg_1. 
Each blocker was given in four equal doses and 
administered cumulatively. We showed that 0.95% 
isoflurane and 1.70% sevoflurane (corresponding 
to 0 .8  MAC of each inhalation anaesthetic, omitting 
the MAC contribution of nitrous oxide) augmented 
and prolonged the neuromuscular block produced 
by vecuronium, pancuronium and atracurium to a 
sim ilar degree. {Br.J, Anaesth. 1996;76:389-395)
cally relevant j for example potentiation of blocker 
effect during administration of sevoflurane and 
reversal of this potentiation on withdrawal of this
may
requirements
decrease the risk of residual curarization after 
operation.
Previous studies comparing effects of iso-
vecuronium
produced inconclusive results. These studies were 
unable to show any significant difference for the 
effects of 1.15% isoflurane and 1.70% sevoflurane 
(both with 70 % nitrous oxide [1, 2]) or for the effects 
of 1.15% isoflurane and 2.05% sevoflurane (both 
with 66 % nitrous oxide [3]) on the block produced
interaction study, com-vecuronium. Another
paring opioid—nitrous oxide-oxygen and opioid
ms oxide-oxygen 
demonstrate anv
% on the
vecuronium
In order to clarify the inconsistencies in the 
literature on the interactions between sevoflurane 
and neuromuscular blockers, we have compared the 
effect of equipotent concentrations of isoflurane and 
sevoflurane on non-depolarizing neuromuscular 
block in a carefully selected, homogeneous popu­
lation of young adults. In this population the
alveolar concentrations (MAC) of iso­
flurane and sevoflurane in air-oxygen were found to
minimum
be % [51 id 2.05 % [6], respectively. The 
% nitrous oxide reduces the MAC
of both agents to
respectively.
% [5] and % [71,
w o rd s
Anaesthetics volatile, isoflurane. Anaesthetics volatile, sevo­
flu ran e . Measurement techniques, electromyography. Measure­
m e n t techniques, mechanomyography. Neuromuscular block, 
vecuronium . Neuromuscular block, pancuronium. Neuromuscu­
lar b lock, atracurium.
M i
Patients and m ethods
After obtaining approval from the Institutional 
Review Board and written informed consent, we 
studied 90 healthy adult patients, aged 18-50 yr, of 
both sexes, ASA I or II, undergoing elective surgical
V arious inhalation anaesthetics augment neuro­
m u scu la r block produced by non-depolarizing
neurom uscular blocking agents to a different degree. 
A lthough  sevoflurane appears to increase both 
in ten sity  and duration of neuromuscular block 
in d u ced  by vecuronium and pancuronium [1-4], the 
m agn itude of this effect has not been quantified in a 
hom ogeneous population. Such information is clini-
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procedures of an anticipated duration of ^  90 min 
under general anaesthesia. Patients were excluded if 
they had cardiac, pulmonary, renal, hepatic, neuro­
logical, psychiatric, muscular, inflammatory, ma­
lignant or endocrine diseases, as were pregnant 
women and patients with recent exposure (<  72 h) 
to medications known to interfere with neuromuscu­
lar transmission. Those more than 20 % overweight, 
according to life insurance tables [8], or those with 
clinical laboratory abnormalities (i.e. serum elec­
trolyte, creatinine, BUN, SGOT, LDH, alkaline 
phosphatase or G G T concentrations) were also 
excluded.
Patients were stratified into one of three blocker 
groups (Vec, Pan, and Atr) consisting of 30 patients 
each. Within each blocker group, patients were 
allocated randomly to one of three anaesthetic 
subgroups, to undergo maintenance of anaesthesia 
with either: (1) alfentanil-nitrous oxide-oxygen 
(non-halogenated anaesthetics group (NHA)) (n 
10); (2) alfentanil-nitrous oxide-oxygen-isoflurane 
(isoflurane group (Iso)) (n =  10); or (3) alfentanil- 
nitrous oxide-oxygen-sevoflurane (sevoflurane
group (Sev)) (n 10).
After an overnight fast, patients were premedica­
ted with diazepam 0.1 mg kg“1 orally, 60-90 min 
before induction of anaesthesia. Before this, patients 
were given Ringer’s solution 1.5 ml kg-1 per hour of 
fasting. Alfentanil 100 \ig kg-1 was administered as a 
bolus i.v. followed by a variable rate infusion of 
alfentanil 0.5-1.5 |j.g kg-1 min“1. Three minutes after 
the alfentanil infusion was started, anaesthesia was 
induced with propofol 3.5-5 mg kg-1 i.v. in divided 
doses. The trachea was intubated without neuro­
muscular block. Anaesthesia was maintained with 
the anaesthetic technique selected during the ran­
domization procedure. End-tidal concentrations of 
isoflurane, sevoflurane and nitrous oxide were tar­
geted at 0.95%, 1.70% and 70% , respectively. For 
the population studied, the MAC values of isoflurane 
and sevoflurane in air-oxygen were defined as 1.15% 
[5] and 2.05%, [6], respectively. The contribution of 
nitrous oxide to the MAC value of the inhalation 
agent was calculated applying the concept of addi­
tivity of MAC fractions, where the individual MAC 
values of each gas (in this case nitrous oxide and 
sevoflurane or isoflurane) are summated to find the 
MAC value of the combination [9]. Equipotent 
concentrations of isoflurane and sevoflurane were 
defined as equal fractions of the MAC of either 
volatile anaesthetic without the MAC contribution 
of nitrous oxide [10].
After 40 min of stable end-tidal anaesthetic con­
centrations (within 5 % of the target values), an end- 
tidal carbon dioxide partial pressure of 4.7-5.3 kPa, 
stable haemodynamics with a systolic arterial pres­
sure > 100  mm Hg and a stable baseline neuro­
muscular transmission recording, the blocker was 
administered i.v. in a cumulative manner, as de­
scribed below. During the procedure both central 
and thenar skin temperatures were maintained 
between 35.5 and 36.5 °C using surface heating.
ECG monitoring of lead II was performed con­
tinuously and arterial pressure was measured in­
termittently by automated sphygmomanometry
(Dinamap, Criticon, Tampa, USA). The arterial
pressure cuff was placed on the arm opposite to the 
site where neuromuscular transmission was assessed. 
Thenar skin temperature was monitored using a 
thermocouple placed on the dorsum of the hand 
from which the response to ulnar nerve stimulation 
was recorded. Central temperature was measured 
using a rectal probe. The end-tidal concentrations of 
carbon dioxide, nitrous oxide, isoflurane and sevo­
flurane were measured continuously and displayed 
by a multiple gas analyser (Capnomac Ultima, 
Datex). This gas analyser was calibrated once every 
week using a calibrating gas (Quick Cal, Datex). 
Neuromuscular transmission was evaluated using 
both the evoked integrated electromyogram (IEM G) 
and the mechanomyogram (MMG) of the ipsilateral 
adductor pollicis muscle. The stimulating current, 
consisting of supramaximal rectangular pulses (dur­
ation 100 (.is) into a train-of-four (TOF) pattern 
(frequency 2 Hz), was generated by the stimulating 
unit of the Datex Relaxograph and delivered every 
20 s (0.05 Hz) to the ulnar nerve at the wrist via s.c. 
27-gauge steel needle electrodes, placed 30 mm 
apart. The hand and forearm were immobilized in 
supination and abduction on a splint and the fingers 
were strapped in extension. The thenar electro­
myographic signal was detected using gelled silver- 
silver chloride skin electrodes. These were placed 
over the belly of the adductor pollicis muscle (the 
active recording electrode), at the distal phalanx of 
the second finger (the reference recording electrode) 
and midway between the stimulating and recording 
electrodes (grounding electrode). The force trans­
ducer was mounted so that the thumb was exposed to 
a preload of 200 g3 measured continuously and 
recorded. D uring the study, a preload of 100-300 g 
was accepted.
For each blocker group, a cumulative dosing 
regimen was designed in which all patients under­
going maintenance of anaesthesia with different 
anaesthetic techniques were given the same amount 
of neuromuscular blocking agent. In the Vec and 
Pan groups, a total dose of 40 jj-g kg-1 of vecuronium 
or pancuronium, respectively, was given and in the 
Atr group a total dose of atracurium 100 jig kg 1 was 
given. Each blocker was injected in four equal doses 
and administered cumulatively. For vecuronium and 
pancuronium, an initial dose of 10 jj,g kg~l and three 
increments of lOfxgkg-1 each were administered. 
For atracurium, an initial dose of 25 p,g k g 1 and 
three increments of 25 (.ig kg-1 each were admin­
istered. Each dose of neuromuscular blocking agent
was injected as an i.v. bolus over < 5 s into a rapidly 
running infusion.
As soon as the patient was anaesthetized, baseline 
evaluations of neuromuscular transmission were 
started and continued for 40 min before admin­
istration of the neuromuscular blocking agent. The 
mean of 10 first twitch (T l) responses, immediately 
preceding the first administration of neuromuscular 
blocking agent, became the control to which all 
subsequent T l  responses were compared. Each dose 
increment was given (at times rl, t2 and r3, 
respectively) only after the effect of the previous dose 
had reached a stable response, defined as three equal
1 Patient characteristics (mean (pooled sem or range)) in the d iffe ren t anaesthetic subgroups within the vecuronium, 
pancuromum and atracurium groups. NHA -  No halogenated anaesthetic („ = 10), Iso =  isoflurane (« =  10), Sev = sevoflurane
(n - 10). % Ideal wt body weight expressed as percentage of ideal weight for height. Within the three blocker groups, there \ 
significant differences between the subgroups NHA, Iso and Sev in age, weight and % ideal wt
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Group
Anaesthetic
technique Age (yr) Weight (kg) % Ideal wt Sex (M/F)
Vecuronium 
(n =  30)
Pancuronium
(n =  30)
Atracurium
(n =  30)
NHA
Iso
Sev
NHA
Iso
Sev
NHA
Iso
Sev
33.2 (19-45)
30.3 (20-47) 
28.9 (19-48)
32.5 (18-46)
33.1 (18-50)
32.6 (21-45)
33.5 (24-47) 
32.8 (21-49)
37.1 (21-50)
67.0 (3.8)
71.3 (3.8)
72.3 (3.8)
63.2 (3.6) 
67.6 (3.6) 
72.5 (3.6)
68.8 (3 .2)
75.0 (3.2)
73.1 (3.2)
97.0 (3.3)
98.2 (3.3) 
102.0 (3.3)
99.4 (3.5) 
101.8 (3.5)
99.4 (3.5)
99.3 (3.6)
102.5 (3.6)
101.5 (3.6)
4/6
7/3
7/3
6/4
4/6
7/3
4/6
4/6
5/5
M n i H i D W  M i r i m i ■ « » u n i i
( ±  1 % ) cons e a 
or w hen 7 min 
from  control.
IEM G  or M M G  T l responses,
passed with no decrease in T l
DATA ANALYSIS
weight and percentage of ideal weight for 
: between the nine subgroups were compared 
one-way analysis of variance (ANOVA). The 
Einot-Gabriel-W esch multiple range test 
(R E G W  test) [11] was applied subsequently to 
iden tify  eventual sources of difference.
W ith in  each blocker group, the time schedule in 
w hich  the four doses of the neuromuscular blocking 
agents were administered was compared between the 
th ree  anaesthetic subgroups, by comparing the times 
to injection of the first (¿1), second (t2) and third
ncrements after administration of the initial 
using one-way ANOVA. The REGW test was 
app lied  subsequently to identify eventual sources of 
difference.
T h e  individual dose-effect relationship was ex­
am ined  by plotting the logarithm of the dose against 
the logit transformation of T l  depression relative to
Logit(E) — a x  log,. D — P
Logit(E) (E /(Em ax—E)); E T l
D
% ) ; Emax = maximal
cumu
M t M M
100 % 
values
J3 = intercept. 
;xist, 0% and 
;d as missing
s of best fit were computed using linear 
least squares regression. The doses required for 
50 % , 90 % and 95 % T l  depression (EDgo, ED9o and 
E D 95, respectively) were calculated from the re­
gression line.
T h e  regression lines were tested to determine if
from
ED«, and ED«,* values were compared
Parallelism
Com
A N O V A  and subsequent REGW  test of the 
ness coefficients of the regression lines (a), 
parison  of the ED50, ED ()0 and ED t)5 values between 
subgroups was performed using one-way ANOVA
REGW
D uration defined as the interval
betw een injection of the last neuromuscular
agent increment to 90% T l  recovery (T90) and  to 
70% T 4/T 1 recovery (TTOF70). T90 and 
TTOF70 were calculated on both the IEM G  and 
MMG by linear intrapolation between the nearest 
neighbour measuring points [13].
In the current study, significant baseline drift with 
time was defined as failure of the IEM G T l  to 
recover to ^  90% of the pre-blocker T l reference 
level, with T 4/T 1 > 0.90. In patients showing 
significant baseline drift with time, the IEM G-based 
T90 was considered as a missing value.
If, within the blocker groups, administration of 
the neuromuscular blocking agent was the same in 
each of the anaesthetic subgroups, T90 and T T O F 70 
values were compared between the anaesthetic 
subgroups by means of one-way ANOVA. T he 
REGW test was applied subsequently to identify the 
source of difference.
Within the anaesthetic subgroups, IEM G-based 
ED50, ED90, ED95, T90 and TTO F70 values were 
compared with the corresponding M M G-based 
variables using the two-tailed paired Student’s t 
tests.
Statistical calculations were performed w ith the 
Statistical Applications Software of the SAS In 
stitute (SA S/STA T Release 6.03, SAS Institu te 
Inc, Cary, USA). All statistical tests were two-sided. 
P  < 0.05 was considered to indicate statistical signifi­
cance.
R esults
We studied 108 patients, but the results from  18 
were excluded because of measurement errors, 
technical failures or deviations from the study 
procedure. W ithin the blocker groups, there were no 
significant differences in age, weight, percentage of 
ideal weight for height or sex distribution between 
the anaesthetic subgroups (table 1).
30)
and sevoflurane (n — 30) were calculated to be  0.82
(se m  0.01) MAC and 0.83 (0.01) MAC, omitting the 
MAC contribution of nitrous oxide, and 1.49 (0.02) 
MAC and 1.50 (0.01) MAC, respectively, including 
the MAC contribution of 70 % nitrous oxide.
Within the blocker groups, the times of adm in­
istration of the first (rl), second (r2) and th ird  dose 
(r3) increments did not differ significantly between 
the anaesthetic subgroups (table 2).
mean
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Table 2 Times (mean (pooled sem)) to cumulative dose 
administration after the initial dose: increments 1, 2 and 3 were 
injected at times T l, T2 and T3, respectively, in the different 
anaesthetic subgroups within the vecuronium, pancuronium 
and atracurium groups. NHA = No halogenated anaesthetic 
(n = 10), Iso = isoflurane (n =  10), Sev = sevoflurane (n = 10). 
Within the three blocker groups, there were no significant 
differences between the subgroups NHA3 Iso and Sev for rl, t2 
or t3
Anaesthetic
Group technique t l  (min) t2 (min) t3 (min)
Vecuronium NHA 5.8 (0.2) 9.8 (0.3) 12.9 (0.3)
(m =  30) Iso 6.1 (0.2) 10.0 (0.3) 13.2 (0.3)
Sev 6.2 (0.2) 10.4 (0.3) 13.5 (0.3)
Pancuronium NHA 6.2 (0.1) 10.0 (0.1) 13.2 (0.2)
(n =  30) Iso 6.3 (0.1) 10.4 (0.1) 13.9 (0.2)
Sev 6.0 (0.1) 10.2 (0.1) 13.4 (0.2)
Atracurium NHA 6.0 (0.1) 10.0 (0,2) 13.4 (0.2)
(n =  30) Iso 6.0 (0.1) 10.1 (0.2) 13.6 (0.2)
Sev 6.1 (0.1) 10.4 (0.2) 13.9 (0.2)
Table 3 Steepness coefficients (mean (pooled s e m ) )  in the 
different anaesthetic subgroups within the vecuronium, 
pancuronium and atracurium groups. NHA = No halogenated 
anaesthetic (n =  10), Iso =  isoflurane (n =  10), Sev =  
sevoflurane (n =  10), The steepness coefficients are the slopes of 
the regression lines, representing the relationship between the 
logit transformation of neuromuscular block and the logarithm 
of the dose. Neuromuscular block was assessed using either 
integrated electromyography (IEMG) or mechanomyography 
(MMG) as an effect variable. Within the three blocker groups, 
there were no significant differences between the subgroups 
NHA, Iso and Sev in steepness coefficients, as determined by 
either IEMG or MMG.
Steepness coefficient
Group technique IEMG MMG
Vecuronium NHA 4.2 (0.2) 4.3 (0.3)
(n — 30) Iso 4.4 (0.2) 3.8 (0.3)
Sev 4.2 (0.2) 3.7 (0.3)
Pancuronium NHA 4.8 (0.2) 4.2 (0.2)
(m = 30) Iso 4.4 (0.2) 3.7 (0.2)
Sev 4.5 (0.2) 3.6 (0.2)
Atracurium NHA 5.1 (0.3) 4.8 (0.4)oCAII Iso 4.6 (0.3) 4.3 (0.4)
Sev 4.3 (0.3) 4.1 (0.4)
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Figure 1 Mean cumulative dose-response relationships for 
vecuronium, pancuronium and atracurium in patients 
undergoing maintenance of anaesthesia in the subgroups : 
opioid-nitrous oxide-oxygen (NHA) (■ ); opioid-nitrous 
oxide-oxygen-isoflurane (Iso) ( # )  and opioid-nitrous 
oxide-oxygen-sevoflurane (Sev) (A)j consisting of 10 patients 
each. The logit transformation of the first twitch (Tl) 
depression is plotted against the logarithm of the cumulative 
dose. The lines were obtained by linear least-squares 
regression, s e m  are illustrated by horizontal (ED50) and vertical 
error bars (T l depression). ^Significant difference (P  <  0.05) 
compared with subgroup NHA. There were no significant 
differences between subgroups Iso and Sev.
Table 4 Cumulative dose-response data for vecuronium, pancuronium and atracurium in the different anaesthetic subgroups. 
NHA =s No halogenated anaesthetic (n = 10), Iso = isoflurane (w = 10), Sev =  sevoflurane (n — 10). ED50, ED90, and ED9g = doses 
producing 50%, 90% and 95% neuromuscular block, respectively, using either integrated electromyography (IEMG) or 
mechanomyography (MMG) as an effect variable (mean (pooled sem)). ^Significant difference (P < 0.05) compared with subgroup 
NHA. There were no significant differences between subgroups Iso and Sev; there were no significant differences between IEMG 
and MMG-based variables
ED50
O-igkg 1)
ED 90 
(HB k g  1)
e d 95
( H g k g
Anaesthetic
Group technique IEMG MMG IEMG MMG IEMG MMG
Vecuronium NHA 23.9(1.7) 24.8 (2.0) 41.6 (3.4) 42.2 (2.9) 50.3 (4.6) 50.9 (3.6)
{n =  30) Iso 16.5 (1.7)* 16.9 (2.0)* 29.1 (3.4)* 30.3 (2.9)* 35.7 (4.6)* 37.1 (3.6)*
Sev 15.0 (1.7)* 14.4 (2.0)* 25.8 (3.4)* 27.6 (2.9)* 31.2(4.6)* 34.9 (3.6)*
Pancuronium NHA 31.7 (1.3) 29.0 (1.4) 49.9 (1.7) 50.0(1.8) 58.1 (2.1) 60.3 (2.3)
(n = 30) Iso 20.7 (1.3)* 20.3 (1.4)* 34.7 (1.7)* 37.2(1.8)* 41.5 (2.1)* 45.9 (2.3)*
Sev 21.3 (1.3)* 21.3 (1.4)* 35.0 (1.7)* 35.9(1.8)* 41.6 (2.1)* 44.6 (2.3)*
Atracurium NHA 117.0 (4.3) 112.4 (4.9) 187.0 (8.0) 177.7 (7.1) 218.7 (10.2) 207.6 (9.2)
(h = 30) Iso 67.8 (4.3)* 66.8 (4.9)* 109.6 (8.0)* 114.7 (7.1)* 129.2 (10.2)* 138.4 (9.2)*
Sev 65.0 (4.3)* 66.5 (4.9)* 108.9 (8.0)* 117.1 (7.1)* 130.0 (10.2)* 142.6 (9.2)*
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T 5 duration of action (m ain (pooled sem)) of vecuronium 40 ng k g ~ \  pancuronium 40 Hg kg"1 and
atracurium 100 jig kg in the different anaesthetic subgroups. NHA = No halogenated anaesthetic (» = 10), Iso
= 10), Sev =  sevoflurane (n = *"' ----  -------is oil ura ne (?j 10). T90, and TTQF70 = times to 90% T1 and 70% T4/T1
“  I ”
eiiect variable. IEMG baseline drift
utgratea electromyography (IEMG) or mechanomyography (MMG) as an
~ number of patients exhibiting failure of the IEMG T1 to recover to ^ 9< 
of the 1 1 reference level, with T4/T1 > 0.9. ^Significant difference (P < 0.05) compared with subgroup NHA.
1 here were no significant differences between subgroups Iso and Sev; there were no significant differences 
between IEMG- and MMG-based variables
Group
Anaesthetic
technique
IEMG
baseline
drift
T90 (min) TTOF70
IEMG MMG IEMG MMG
Vecuronium
„ - i t e  J  ^
NHA
4 P
2 38.9(6.1) 35.6 (5.7) 39.4 (4.3) 40.5 (5.4)
(fl K3 30) Iso 3 60.1 (6.5)* 58.8 (5.7)* 62.4 (4.5)* 60.9 (5.4)*
Sev 1 67.3 (5.7)* 58.1 (5.7)* 67.9 (4.1)* 70.5 (5.4)*
Pancuronium
t  *  ~  y  u  • _
NHA 1 57.9 (7.0) 57.4 (9.3) 60.5(9.1) 67.1 (9.3)
(n = 30) Iso 2 104.8 (7.3)* 111.6(9.3)* 127.1 (9.7)* 135.8 (9.3)*
Sev 4 93.1 (7.9)* 105.6 (9.3)* 118.5 (11.5)* 126.4 (9.3)*
Atracurium
—?  . j W  r  'm
NHA 0 28.2 (9.5) 25.9 (2.5) 28.7 (2.6) 30.5 (2.1)
(n «  30) Iso 0 50.7 (9.5)* 50.3 (2.5)* 48.1 (2.6)* 50.1 (2.1)*
Sev 1 49.6 (9.7)* 45.0 (2.5)* 50.8 (2.8)* 50.9 (2.1)*
d u n n i n g » » * * *
F o r the blocker groups, the slopes of the cumu­
lative dose-response curves did not differ signifi­
cantly  between the anaesthetic subgroups (table 3). 
T h e  E D 50j EDt,0 and ED95 values, calculated for the 
subgroups Iso and Sev, were not significantly 
different. There was a significant difference in ED50, 
E D ,h, and ED<)5 values (P  < 0.01) between the 
subgroups receiving halogenated volatile anaes­
thetics (Iso and Sev) and the subgroup receiving 
opioid—nitrous oxide-oxygen anaesthesia (NHA) 
(tab le 4, fig. 1). There were no significant differences 
betw een the E D 5(„ ED,,0 and ED,,5 values determined 
using  the IEM G  or M M G.
In  the blocker groups, T90 and TTOF70, meas-
the subgroups Iso and Sev, were not
significantly different. There was a significant dif­
ference in T90 and TTO F70 (P < 0.01) between the 
subgroups receiving the halogenated volatile anaes-
and the subgroup receiving opioid-nitrous 
oxide-oxygen anaesthesia (table 5).
ourteen patients exhibited significant IEMG 
baseline drift with time. Within the blocker groups, 
th e re  were no significant differences between IEMG-
M M G-based T90 values for the patients
no significant baseline drift with time. 
A lso, there were no significant differences between 
IE M G - and M M G-based TTO F70 values in all 
patients.
Discussion
W e have demonstrated that equipotent concen­
trations of isoflurane and sevoflurane (i.e. 0.95 % and 
1 .70% , respectively) augmented and prolonged
and atracurium- 
: to a similar degree
vecuronium pancuronium
with opioid-nitrous oxide anaesthesia. 
T h e  concentrations of isoflurane and sevoflurane
to 0.8 MAC, omitting the MAC 
contribution of nitrous oxide, and to 1.5 MAC, 
including the MAC contribution of 70% nitrous
oxide.
T he  current interaction study differed from pre­
vious ones [1-41 in that anaesthetic-related effects on
neuromuscular blocking agents were compared with­
in a carefully selected homogeneous population of 
young adults, using IEM G and M M G responses of 
the adductor pollicis brevis muscle simultaneously.
MAGNITUDE OF BLOCK
If administered in equipotent concentrations, in­
halation anaesthetics enhanced vecuronium-, pan­
curonium- and atracurium-induced neuromuscular 
block to an approximately equal extent. The IEM G 
and MMG tend to detect similar magnitudes of 
block after administration of either vecuronium, 
pancuronium or atracurium. Similar observations 
have been made previously with tubocurarine [14]. 
The results of the current study are at variance with 
those of Engbæk and Roed [15] using pancuronium. 
Their findings may be explained by different con­
ditions of anaesthesia, or recording electrode 
positioning [16] and stimulation frequency, or both
[17].
The MMG-based potency estimates, assessed in 
the current study with an opioid-nitrous oxide- 
oxygen anaesthetic, were consistent with previously 
determined values for vecuronium [18, 19], pan­
curonium [20] and atracurium [18, 19] using the 
cumulative dose technique.
Our conclusions regarding the effect of isoflurane 
and sevoflurane on non-depolarizing neuromuscular 
block are in keeping with those of Morita and co­
workers [3] who were unable to detect any significant 
difference between the potentiating effects of 1.15 % 
isoflurane and 2.05% sevoflurane in 66% nitrous 
oxide (i.e. 1 MAC of either vapour in oxygen-air 
without the MAC contribution of nitrous oxide) on 
neuromuscular block produced by vecuronium. 
However, the ED 50, ED 90 and ED95 values calculated, 
using the single dose technique, were less than the 
current cumulative dose values. Redistribution be­
tween successive cumulative doses may explain the 
greater ED 50, ED 90 and ED95 estimates in the current 
study. Moreover, the end-tidal concentrations of 
isoflurane and sevoflurane in their study (1.15 and 
2.05%, respectively) were approximately 20%
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higher than those used in the current study (0.95 and 
1.70%, respectively). Additionally, there may be 
other factors (i.e. anthropometric, ethnic [21] or 
environmental [22]) that could have affected the 
sensitivity to vecuronium.
The cumulative dose technique, used in the 
current study, may underestimate the potency of the 
neuromuscular blocking agent with rapid distri­
bution and elimination. However, administration of 
a neuromuscular blocking agent was consistent 
throughout the study and the volatile agent was 
chosen randomly ; thus the degree of redistribution 
would have been similar in all patients within a 
blocker group undergoing maintenance of anaes­
thesia with different techniques. Additionally, the 
aim of the current study was to determine anaes­
thesia-related effects on non-depolarizing neuro­
muscular block and not to provide absolute potency 
estimates.
DURATION OF ACTION
In equipotent concentrations, both inhalation anaes­
thetics prolonged vecuronium-, pancuronium- and 
atracurium-induced neuromuscular block to a simi­
lar degree. The IEM G - and M M G-based TTO F70 
values may be used interchangeably for the three 
neuromuscular blocking agent studied. Similar find­
ings have been shown previously for atracurium [23] 
and tubocurarine [14]. However, during offset of 
neuromuscular block, IEM G  T1 should be inter­
preted with caution as it may be unstable with time. 
The M M G-based T90 values assessed in the current 
study were comparable with previously published 
M M G T90 values during opioid-nitrous oxide- 
oxygen anaesthesia for vecuronium [24, 25], pan­
curonium [26] and atracurium [27] and during 
opioid-nitrous oxide-isoflurane anaesthesia for atra­
curium [27, 28].
Recent studies on the effect of sevoflurane on 
duration of vecuronium-induced neuromuscular 
block yielded data that showed wide variation on the 
extent of prolongation [2-4]. However, there were 
several methodological differences compared with 
our study. First, in these studies, patient ages ranged 
from 22 to 77 yr [2], 22 to 62 yr [3] and 25 to 75 yr 
[4], respectively. Second, offset of neuromuscular 
block was measured using the evoked IEM G , which 
was shown to be unreliable in 5-42%  (18% in the 
current study) of patients [29]. As advancing age is 
associated with a greater incidence of slow recovery 
after vecuronium [5], and because the IEM G  is 
unreliable during offset of non-depolarizing neuro­
muscular block [30], considerable between-patient 
variability in duration of neuromuscular block may 
have been produced within the populations studied. 
In the investigation of Saitoh, Toyooka and Amaha 
[2], the scatter in the duration of neuromuscular 
block, after the same dose of vecuronium 
(0.2 mg kg-1) was so large that significant differences 
in the duration of neuromuscular block with opioid- 
nitrous oxide and opioid-nitrous oxide-isoflurane 
(end-tidal isoflurane concentration = 1.15%) anaes­
thesia could not be demonstrated. Therefore, com­
parison of such inaccurately determined recovery
variables between these heterogeneous populations 
produces results that should be interpreted with 
caution.
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